Vicore informs on clinical programs in relation to the current outbreak of COVID-19

Report this content

Gothenburg, March 20, 2020 – Vicore Pharma informs on clinical programs in relation to the current outbreak of COVID-19.

The on-going clinical study of Raynaud’s phenomenon in patients with systemic sclerosis, in which effects of C21 on blood flow are being studied, has recruited faster than planned. However the clinical trial work will now slow down by trial participants avoiding non-essential hospital visits.

“Ensuring safety of trial participants is paramount and based on the performance so far I believe we will be able to swiftly catch up and still report the results by the end of the year, as originally planned”, says Carl-Johan Dalsgaard, CEO of Vicore Pharma.

The application to start the phase II study in patients with Idiopathic Pulmonary Fibrosis (IPF) where we aim to offer a significant therapeutic benefit to patients is expected to be filed by the end of this month as scheduled and the COVID-19 situation has not had any impact on that submission. The company anticipates recruitment of patients to the trial to start in Q3 2020.

For further information, please contact:

Carl-Johan Dalsgaard, CEO, tel: +46 70 975 98 63,  

About Vicore Pharma Holding AB (publ)

Vicore Pharma is a rare disease pharmaceutical company focused on interstitial lung diseases and related indications. The company currently has two drug development programs, VP01 and VP02. 

VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (“IPF”) and pulmonary fibrosis in systemic sclerosis (“SSc”). VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound (an “IMiD”). VP02 focuses on the underlying disease and the severe cough associated with IPF. VP01 and VP02 are also being actively evaluated for other indications within the field of interstitial lung diseases which have a significant unmet need. 

The company's shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see